AstraZeneca Advances Oral GLP-1 Elecoglipron into Phase 3 Trials
AstraZeneca (AZN) has advanced its oral GLP-1 drug, elecoglipron, to phase 3 trials following positive mid-stage results in weight loss and type 2 diabetes. The phase 2b VISTA trial showed significant outcomes for obese or overweight patients.
Tickers: $AZN
Topics: GLP-1 drugs pharmaceuticals type 2 diabetes weight loss